Welcome to our dedicated page for Immuron news (Ticker: IMRN), a resource for investors and traders seeking the latest updates and insights on Immuron stock.
Immuron Ltd (ASX: IMRN) provides investors and industry stakeholders with timely updates through this centralized news resource. Track the Australian biopharmaceutical innovator's progress in developing oral immunotherapies targeting gastrointestinal and immune-mediated disorders.
Access verified announcements covering clinical trial milestones, regulatory developments, and strategic partnerships. Our curated collection includes updates on Immuron's hyperimmune bovine colostrum platform, product pipeline advancements, and financial disclosures - all essential for understanding the company's position in the immunotherapy sector.
Key focus areas include Travelan® commercialization efforts, research into non-alcoholic fatty liver disease treatments, and novel applications of polyclonal antibody technology. Bookmark this page for efficient monitoring of Immuron's progress in addressing unmet needs across gastroenterology and immunology markets.
Immuron (NASDAQ: IMRN) has reported its highest sales figures in history for its over-the-counter immune supplement Travelan®. The company achieved record global sales exceeding AUD$5.3 million year-to-date, marking a 46% increase compared to the previous year.
Regional performance shows strong growth in North America, with quarterly sales of AUD$0.5 million (up 28%) and year-to-date sales of AUD$1.6 million (up 86%). Australian operations recorded AUD$0.8 million for the March 2025 quarter (down 8%), while year-to-date sales reached AUD$3.7 million (up 34%).
Travelan® has achieved significant market positioning in Australia, ranking #1 by market share change and #2 by SKU in the Anti-diarrheal category. The company reports strong momentum in both USA and Canada, with successful direct-to-consumer marketing and major retailer listings respectively.
Immuron (NASDAQ: IMRN) has entered into an exclusive distribution agreement to launch ProIBS® in Australia and New Zealand for treating Irritable Bowel Syndrome (IBS) symptoms. The product will join Immuron's portfolio alongside Travelan®.
ProIBS®, developed by Calmino group AB, contains AVH200® derived from Aloe barbadensis Miller and supports the intestinal mucosal barrier. A usability study with 1,003 users showed impressive results: 94% found it helpful, 91% experienced improved daily life, and 98% would recommend it.
The Australian IBS treatment market, part of the 'Digestives & Intestinal Remedies' sector, is projected to generate AU$221.14 million in 2025, with a 3.28% annual growth rate. IBS affects approximately 30% of people, predominantly females, causing symptoms like abdominal pain, bloating, and irregular bowel movements.
Immuron (IMRN) reported strong sales growth for its over-the-counter immune supplement Travelan® in the December 2024 quarter. Global sales reached AUD$2.5 million, marking a 70% increase from the previous quarter and a 249% rise year-over-year.
In Australia, quarterly sales hit AUD$1.9 million, up 83% from the previous quarter and 314% year-over-year, while half-year sales reached AUD$2.9 million, a 54% increase. The growth reflects expanded distribution across nine additional pharmacy banner groups.
In North America, quarterly sales reached AUD$0.7 million, up 43% quarter-over-quarter and 141% year-over-year. Half-year sales grew to AUD$1.1 million, with USA contributing AUD$0.731 million and Canada AUD$0.376 million, benefiting from distribution across ten pharmacy/grocery retailers in Canada and growing amazon.com sales.
Immuron (NASDAQ: IMRN) has announced a new research collaboration with Monash University to develop therapeutic drug candidates targeting antimicrobial resistant pathogens. The collaboration involves two key projects: one focusing on bacterial DNA transfer mechanisms to develop broad-spectrum therapeutics, and another specifically targeting Vancomycin-resistant enterococci (VRE).
The research will utilize Immuron's technology platform and will be led by Professor Dena Lyras at the Biomedicine Discovery Institute. The collaboration requires no additional funding beyond Immuron's existing research budget. After initial results, both parties will negotiate potential joint development or commercialization terms.
The initiative addresses a critical healthcare challenge, with antimicrobial resistance (AMR) treatment costs exceeding $4.6 billion annually in the U.S. The global antibiotics market is projected to reach $57.0 billion by 2026, growing at a 4.0% CAGR.
Immuron (NASDAQ: IMRN) has submitted a Clinical Study Report to the FDA for its completed Travelan® (IMM-124E) Phase 2 trial, with plans to request an end of Phase 2 meeting before proceeding to Phase 3. The study demonstrated statistically significant results in both immunology and microbiome responses.
The trial showed lower IgA and IgG levels in Travelan®-treated subjects compared to placebo, indicating reduced ETEC antigen exposure. There was also a significant reduction in colony forming units in subjects' stools after 48 hours (p=0.0121), suggesting faster pathogen clearance.
Microbiome analysis revealed that the Travelan® group maintained more stable gastrointestinal microbiota, with improved richness and diversity compared to placebo. The treatment group showed increased levels of beneficial bacteria and reduced inflammation-associated bacteria.
Additionally, a separate Uniformed Services University field study has randomized 776 subjects, with final enrollments expected in March 2025 and follow-up completion around June 2025.
Immuron (NASDAQ: IMRN) announces CEO Steven Lydeamore's upcoming presentation at the Small Cap Growth Virtual Investor Conference on December 5th, 2024, at 2:30 PM EST. The interactive online event allows real-time investor questions and will be archived for later viewing.
Recent highlights include a 172% increase in global sales to $4.90 million in FY24, with record Travelan® sales of $4.86 million. October 2024 saw record monthly sales of A$1.49 million. The company reports ~90% recruitment for the Travelan® Uniformed Services University Phase 4 trial and is planning a Phase 2 trial for IMM-529 following positive FDA pre-IND feedback.
Immuron (ASX: IMC; NASDAQ: IMRN) announced that CEO Steven Lydeamore delivered a presentation at the 21st Virtual Investor Summit Microcap Event on November 21. The company has made the presentation materials available on their corporate website under the presentations section.
Immuron (NASDAQ:IMRN) has announced its participation in the upcoming Q4 Virtual Investor Summit Microcap Event on November 21st. The company, which specializes in gut mediated diseases with one commercial product and two pipeline assets across three clinical programs, will deliver a presentation from 10:30am to 11:00am ET. The event features 40 micro-cap companies with catalysts and/or strong market performance. One-on-one meetings will be available throughout the day, and qualified investors can attend the event complimentarily, which includes live Q&A sessions.
Immuron (ASX: IMC; NASDAQ: IMRN) has announced that its Chief Executive Officer, Steven Lydeamore, will participate in a fireside chat at the Maxim Virtual Healthcare Conference on Wednesday, 16th October 2024, at 4:30 PM U.S. Eastern time. The company has made available a copy of the presentation covering the information to be discussed during the event on their official website. Interested parties can access the presentation materials at https://www.immuron.com.au/corporate-presentations/. This announcement has been authorized by Immuron 's board of directors.
Immuron (ASX: IMC; NASDAQ: IMRN) has reported strong sales growth for its over-the-counter immune supplement Travelan® in the September 2024 Quarter. Global sales reached AUD$1.5 million, up 13% from the previous quarter. In Australia, sales increased by 3% to AUD$1.007 million, while North American sales saw a significant jump of 48% to AUD$0.456 million.
Chief Commercial Officer Flavio Palumbo highlighted the company's achievements, including securing core ranging in nine additional Australian pharmacy banner groups, achieving the strongest monthly sales on amazon.com in the US, and expanding distribution to ten pharmacy/grocery retailers in Canada. These developments have contributed to Immuron's continued growth in both the Australian and North American markets.
